查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2129025

骶髂關節疾病治療市場：依療法、藥物、診斷、最終用戶、國家及地區分類－產業分析、市場規模、市佔率及2026年至2033年預測

Sacroiliitis Treatment Market, By Treatment Type, By Medication Type, By Diagnosis, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 364 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，骶髂關節炎治療市場規模將達到 23.601 億美元，並有望從 2026 年到 2033 年以 6.6% 的複合年成長率成長。

骶髂關節炎的治療方法包括介入治療、物理治療和手術治療，用於控制僵直性脊椎炎關節的發炎和疼痛。可用的治療方法包括非類固醇消炎劑（NSAIDs）、鎮痛藥、皮質類固醇注射、生物製藥和其他療法。乾癬性關節炎關節炎、中軸型脊椎關節炎、創傷和其他發炎性疾病均與骶髂關節炎有關。

骶髂關節發炎治療市場—市場動態

發炎性和慢性肌肉骨骼疾病的日益普遍，以及骶髂關節治療的日益普及，預計將推動市場需求。

發炎性肌肉骨骼疾病的日益普遍是骶髂關節炎治療市場的主要促進因素。骶髂關節炎通常與中軸型脊椎關節炎、僵直性脊椎炎和乾癬性關節炎等發炎性疾病有關，這些疾病可導致持續性疼痛、僵硬和活動範圍受限。隨著對這些疾病的認知和診斷技術的進步，人們越來越需要有效的治療方法來減輕發炎並保護關節功能。生物製藥治療的重要性日益凸顯，尤其對於中度及重度發炎性疾病患者而言。 TNF抑制劑（如Adalimumab、Etanercept、Infliximab和戈利木單抗）以及IL-17抑制劑（如塞替單抗和伊克珠單抗）是常用的治療選擇。此外，醫生對該疾病認知的提高、影像學和診斷技術的進步以及發炎性骶髂關節炎的早期發現，都在加速治療方法的普及，並推動市場成長。

推動骶髂關節炎治療市場擴張的主要因素是微創手術技術的日益普及。對於保守治療效果不佳的退化性骶髂關節炎或骶髂關節功能障礙患者，可考慮採用微創骶髂關節融合術，以達到長期緩解疼痛和穩定關節。醫療設備製造商正在研發植入和手術技術，以支撐骶髂關節，同時減少組織損傷、出血和恢復時間。Medtronic為某些類型的退化性骶髂關節炎或骶髂關節破壞患者提供“Rialto SI融合系統”，而SI-BONE公司的“iFuse系統”則是專為微創骶髂關節融合術而設計的。多孔鈦材料的研發、更小巧、更符合解剖結構的植入、影像引導導航技術以及手術技術的改進，都進一步促進了微創手術的普及。

骶髂關節發炎治療市場—細分分析：

全球骶髂關節發炎治療市場按治療類型、藥物類型、診斷、最終用戶和地區進行細分。

治療方法分為五類：藥物治療、關節內注射、射頻消融術、骶髂關節融合術等。藥物治療佔據了大部分收入。非類固醇抗發炎藥和鎮痛藥廣泛用於減輕疼痛和炎症，而皮質類固醇可透過局部注射用於靶向緩解症狀。患有與中軸型脊椎關節炎相關的發炎性骶髂關節炎的患者可使用生物製藥進行治療。

骶髂關節疾病治療市場—區域分析

北美在骶髂關節炎治療市場佔據主導地位，這得益於生物製藥的廣泛應用、成熟的風濕病和疼痛管理服務，以及許多製藥和醫療設備公司的強大實力。美國仍然是主要市場，這主要得益於先進的發炎性疾病療法的普及以及微創骶髂關節融合術的日益普及。亞太地區正崛起為一個極具吸引力的成長市場，這得益於醫療基礎設施的完善、醫療支出的成長、人們對發炎性肌肉骨骼疾病認知的提高，以及生物製藥和先進外科手術治療的普及。中國、日本、印度、韓國和澳洲是推動該地區成長的關鍵市場。預計拉丁美洲在預測期內將保持溫和成長。

目錄

第1章：骶髂關節疾病治療市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：薦髂關節疾病治療的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：骶髂關節治療產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：骶髂關節疾病治療市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：骶髂關節疾病治療市場趨勢

  • 2025年骶髂關節發炎治療市佔率分析
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章：骶髂關節疾病治療市場：依治療類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按治療類型
    • 製藥
    • 關節內注射
    • 射頻消融術
    • 骶髂關節融合手術
    • 其他

第8章：骶髂關節炎治療市場：依藥物類型分類

  • 概述
    • 細分市場佔有率分析：依藥物類型分類
    • NSAIDs
    • 止痛藥
    • 皮質類固醇
    • TNF抑制劑
    • 其他

第9章：薦髂關節炎治療市場：依診斷分類

  • 概述
    • 基於細分市場的市佔率分析：按診斷
    • 身體檢查
    • X光
    • 磁振造影（MRI）
    • 電腦斷層掃描（CT）
    • 其他

第10章 骶髂關節疾病治療市場：依最終使用者分類

  • 概述
    • 基於細分市場的市場佔有率分析：按最終用戶分類
    • 醫院
    • 專科診所
    • 門診手術中心
    • 其他

第11章：骶髂關節疾病治療市場：按地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他中東和非洲國家

第12章：主要供應商分析：骶髂關節治療產業

  • 競爭對手儀錶板
    • 競爭基準
    • 競爭定位
  • 公司簡介
    • Pfizer Inc.
    • Johnson & Johnson
    • AbbVie Inc.
    • Novartis AG
    • Eli Lilly and Company
    • Boehringer Ingelheim International GmbH
    • Amgen Inc.
    • UCB SA
    • Sandoz Group AG
    • Samsung Bioepis Co., Ltd.
    • Celltrion Healthcare Co., Ltd.
    • Globus Medical, Inc.
    • Orthofix Medical Inc.
    • SI-BONE, Inc.
    • Medtronic plc
    • Others

第13章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7356

Sacroiliitis Treatment Market size was valued at USD 2,360.1 Million in 2025, expanding to a CAGR of 6.6% from 2026 to 2033.

The sacroiliitis treatment include interventional procedures, physical therapies, and surgical solutions used to manage inflammation and pain affecting the sacroiliac joints. Nonsteroidal anti-inflammatory medications (NSAIDs), analgesics, corticosteroid injections, biologic therapy, and other treatments are available. Ankylosing spondylitis, psoriatic arthritis, axial spondyloarthritis, trauma, and other inflammatory diseases are associated to sacroiliitis.

Sacroiliitis Treatment Market- Market Dynamics

Growing prevalence of inflammatory & chronic musculoskeletal disorders and adoption of sacroiliac joint procedures are expected to propel market demand

The rising prevalence of inflammatory musculoskeletal disorders is a key factor driving the growth of the sacroiliitis treatment market. Sacroiliitis is commonly associated with inflammatory conditions such as axial spondyloarthritis, ankylosing spondylitis, and psoriatic arthritis, which can cause persistent pain, stiffness, and reduced mobility. The need for efficient treatments targeted at reducing inflammation and preserving joint function is growing as knowledge and diagnosis of these disorders advance. Particularly for individuals with moderate-to-severe inflammatory diseases, biologic treatments have grown in importance. TNF inhibitors like adalimumab, etanercept, infliximab, and golimumab, as well as IL-17 inhibitors like secukinumab and ixekizumab, are often utilized choices. In addition, growing physician awareness, advances in imaging and diagnostic techniques, and earlier identification of inflammatory sacroiliac joint disease are contributing to greater treatment adoption and supporting market growth.

The market for sacroiliitis treatments is expanding due in large part to the growing use of minimally invasive techniques. In order to attain longer-term pain alleviation and joint stabilization, patients with degenerative sacroiliitis or sacroiliac joint dysfunction who do not respond well to conservative therapy may have minimally invasive sacroiliac joint fusion. In order to support the sacroiliac joint while reducing tissue damage, blood loss, and recovery time, medical device manufacturers are developing implants and surgical techniques. While Medtronic provides the Rialto SI Fusion System for certain patients with degenerative sacroiliitis or SI joint disruption, SI-BONE's iFuse systems are specifically made for minimally invasive SI joint fusion. The use of minimally invasive surgery is being further supported by developments in porous titanium materials, smaller and anatomically tailored implants, image-guided navigation, and better surgical procedures.

Sacroiliitis Treatment Market- Segmentation Analysis:

The Global Sacroiliitis Treatment Market is segmented on the basis of Treatment Type, Medication Type, Diagnosis, End User, and Region.

The market is divided into five categories based on Treatment Type: medications, joint injections, radiofrequency ablation, sacroiliac joint fusion, and others. The medication segment held the large chunk of revenue in the treatment type. NSAIDs and analgesics medications are widely used to reduce pain and inflammation, while corticosteroids may be administered through local injections for targeted symptom relief. Patients with inflammatory sacroiliitis associated with axial spondyloarthritis may receive biologic therapies.

Sacroiliitis Treatment Market- Geographical Insights

North America holds a leading position in the sacroiliitis treatment market, supported by extensive use of biologic medicines, well-established rheumatology and pain management services, and robust presence of pharmaceutical and medical device companies. The United States remains a key market, driven by the availability of advanced inflammatory-disease treatments and increasing adoption of minimally invasive sacroiliac joint fusion procedures. Asia-Pacific is emerging as an attractive growth market, supported by improving healthcare infrastructure, rising healthcare expenditure, greater awareness of inflammatory musculoskeletal disorders, and expanding access to biologic therapies and advanced surgical treatments. China, Japan, India, South Korea, and Australia are among the key markets contributing to regional development. Latin America is expected to grow moderately during the forecast period.

UK Sacroiliitis Treatment Market- Key Insights

The UK has a substantial patient population affected by axial spondyloarthritis and other inflammatory conditions involving the sacroiliac joints. Treatment typically includes pharmacological therapies, physiotherapy, specialist rheumatology care, and biologic treatments for eligible patients with persistent or moderate-to-severe disease. Patients with inflammatory sacroiliac joint problems now have more therapy choices thanks to the increasing availability of targeted biologic treatments. For the treatment of axial inflammatory illnesses, TNF inhibitors and IL-17 inhibitors continue to be crucial therapeutic classes, especially for patients who do not respond well to traditional treatments. Additionally, the UK is a significant market for pharmaceutical research, clinical development, and the commercialization of cutting-edge treatments for inflammatory diseases. For example, UCB's BIMZELX (bimekizumab) has generated clinical evidence in axial spondyloarthritis, while other leading pharmaceutical companies continue to develop and commercialize targeted therapies aimed at improving outcomes for patients with inflammatory conditions.

Sacroiliitis Treatment Market- Competitive Landscape:

The market for sacroiliitis treatments is moderately competitive. By developing biologic medicines, targeted immunomodulators, biosimilars, increased therapeutic indications, clinical research, etc., major pharmaceutical companies are bolstering their position in the sacroiliitis treatment market. The market demand is being supplemented by the expanding development of targeted biologic medicines. Inflammatory sacroiliitis linked to axial spondyloarthritis and other inflammatory conditions can now be effectively treated with TNF inhibitors and IL-17 inhibitors. To increase efficacy, safety, and long-term illness control, businesses are funding clinical research and next-generation treatments. While promoting greater patient access to cutting-edge medicines, the growing availability of less expensive alternatives is escalating rivalry with well-established biologic medications.

Recent Developments:

In April 2025, Johnson & Johnson continued strengthening its immunology portfolio through the development of TREMFYA(R) (guselkumab). The company announced positive Phase 3b APEX trial results in patients with active psoriatic arthritis, highlighting improvements in clinical symptoms and the progression of structural joint damage.

In June 2025, UCB strengthened its position in inflammatory musculoskeletal disease by presenting three-year BIMZELX (bimekizumab) data at EULAR 2025 event, demonstrating sustained efficacy and long-term inflammation control in patients with axial spondyloarthritis.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SACROILIITIS TREATMENT MARKET KEY PLAYERS

  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Amgen Inc.
  • UCB SA
  • Sandoz Group AG
  • Samsung Bioepis Co., Ltd.
  • Celltrion Healthcare Co., Ltd.
  • Globus Medical, Inc.
  • Orthofix Medical Inc.
  • SI-BONE, Inc.
  • Medtronic plc
  • Others

GLOBAL SACROILIITIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020-2033

  • Medications
  • Joint injections
  • Radiofrequency ablation
  • Sacroiliac joint fusion
  • Others

GLOBAL SACROILIITIS TREATMENT MARKET, BY MEDICATION TYPE- MARKET ANALYSIS, 2020-2033

  • NSAIDs
  • Analgesics
  • Corticosteroids
  • TNF Inhibitors
  • Others

GLOBAL SACROILIITIS TREATMENT MARKET, BY DIAGNOSIS- MARKET ANALYSIS, 2020-2033

  • Physical Examination
  • X-ray
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Others

GLOBAL SACROILIITIS TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2020-2033

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

GLOBAL SACROILIITIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020-2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Sacroiliitis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Sacroiliitis Treatment Market Snippet by Treatment Type
    • 2.1.2. Sacroiliitis Treatment Market Snippet by Medication Type
    • 2.1.3. Sacroiliitis Treatment Market Snippet by Diagnosis
    • 2.1.4. Sacroiliitis Treatment Market Snippet by End User
    • 2.1.5. Sacroiliitis Treatment Market Snippet by Country
    • 2.1.6. Sacroiliitis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Sacroiliitis Treatment Key Market Trends

  • 3.1. Sacroiliitis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Sacroiliitis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Sacroiliitis Treatment Market Opportunities
  • 3.4. Sacroiliitis Treatment Market Future Trends

4. Sacroiliitis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Sacroiliitis Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Sacroiliitis Treatment Market Landscape

  • 6.1. Sacroiliitis Treatment Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Sacroiliitis Treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
    • 7.1.2. Medications
    • 7.1.3. Joint injections
    • 7.1.4. Radiofrequency ablation
    • 7.1.5. Sacroiliac joint fusion
    • 7.1.6. Others

8. Sacroiliitis Treatment Market - By Medication Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Medication Type, 2025 & 2033 (%)
    • 8.1.2. NSAIDs
    • 8.1.3. Analgesics
    • 8.1.4. Corticosteroids
    • 8.1.5. TNF Inhibitors
    • 8.1.6. Others

9. Sacroiliitis Treatment Market - By Diagnosis

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Diagnosis, 2025 & 2033 (%)
    • 9.1.2. Physical Examination
    • 9.1.3. X-ray
    • 9.1.4. Magnetic Resonance Imaging (MRI)
    • 9.1.5. Computed Tomography (CT)
    • 9.1.6. Others

10. Sacroiliitis Treatment Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Ambulatory Surgical Centers
    • 10.1.5. Others

11. Sacroiliitis Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Sacroiliitis Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Sacroiliitis Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Sacroiliitis Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Sacroiliitis Treatment Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Sacroiliitis Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Sacroiliitis Treatment Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Pfizer Inc.
    • 12.2.2. Johnson & Johnson
    • 12.2.3. AbbVie Inc.
    • 12.2.4. Novartis AG
    • 12.2.5. Eli Lilly and Company
    • 12.2.6. Boehringer Ingelheim International GmbH
    • 12.2.7. Amgen Inc.
    • 12.2.8. UCB SA
    • 12.2.9. Sandoz Group AG
    • 12.2.10. Samsung Bioepis Co., Ltd.
    • 12.2.11. Celltrion Healthcare Co., Ltd.
    • 12.2.12. Globus Medical, Inc.
    • 12.2.13. Orthofix Medical Inc.
    • 12.2.14. SI-BONE, Inc.
    • 12.2.15. Medtronic plc
    • 12.2.16. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us